|
Workshop
[Free Online Workshop] Unleashing the Power of Real-World Evidence / Data (RWE/RWD) to Facilitate Drug Discovery, Development, and Beyond
Speakers:
Lixia Yao, Polygon Health Analytics LLC; Aaron Mackey, Lokavant; Ying Li, Regeneron Pharmaceuticals, Inc.; Daisuke Goto, Organon & Co.; Star Chen, Merck & Co.
Organizers:
Lixia Yao - Founder & CEO, Polygon Health Analytics LLC
Date:
2024-10-25
Time:
8:30-12:00 Pacific Time
Registration fee:
Free
Location:
Online via Zoom
Major Sponsor:
Vendor show vendors registered to date:
Registration: http://www.PBSS.org
Registration deadline:2024-10-24
(it will close sooner if the seating cap is reached)
About the Topic
Real-world data (RWD) are data relating to patient health status and/or the delivery of health care routinely collected from a variety of sources, and Real-world evidence (RWE) is the clinical evidence about the usage and potential benefits or risks of a medical product derived from analysis of RWD. In this workshop, we delve into the transformative power of RWD and RWE in the pharmaceutical industry, which may transform every facet of the pharma industry from discovery to marketing.
The following topics will be covered:
- Definitions, sources, and implications of RWD and RWE in today’s healthcare landscape.
- RWD and RWE for drug discovery, highlighting how RWD can identify new therapeutic targets and accelerate new drug discovery
- The role of RWD in clinical development, including designing innovative trials, enhancing patient recruitment, and improving outcomes
- Health Economics and Outcome Research (HEOR), demonstrating the potential of RWD/RWE in cost-effectiveness analysis, budget impact analysis, and health technology assessment
- Strategic utilization of RWD in pharma marketing, discussing how it can inform strategies, support product positioning, and provide insights into market dynamics
- FDA's approaches on RWD and RWE for drug approval and regulation
Time (PST) |
Topic |
Presenter(s) |
8:30 – 8:45 am |
PBSS Welcome and Introduction |
Shichang Miao, PhD, PBSS |
8:45 – 9:25 am |
Introduction to Real-world Data and Real-world Evidence |
Lixia Yao, PhD, Founder & CEO, Polygon Health Analytics LLC |
9:25 – 10:05 am |
Real-world Data for Drug Discovery |
Aaron Mackey, PhD, SVP, AI & Data Science, Lokavant |
10:05 – 10:45 am |
Real-world Data for Clinical Development |
Ying Li, PhD, Director, RWE and advanced analytics, Regeneron Pharmaceuticals, Inc. |
10:45 – 11:25 am |
Real-world Data for Health Economics and Outcome Research (HEOR) |
Daisuke Goto, PhD, Director, Medical Affairs and Outcomes Research, Organon & Co. |
11:25 am – 12:00 pm |
Panel Discussion |
Lixia Yao, Polygon Health Analytics LLC; Aaron Mackey, Lokavant; Ying Li, Regeneron Pharmaceuticals, Inc.; Daisuke Goto, Organon & Co.; Star Chen, Merck & Co. |
2024-09-10, [In-Person] Translational PK/PD and Human Dose Projection for Antibodies/ADCs and Novel Therapeutic Modalities
|
2024-09-20, [In-Person] Nonclinical Safety Assessments of Biologics and Other Novel Modalities for IND/NDA/BLA Filings
|
2024-09-25, [Free Online] Development of Protein Degraders: Computational Modeling, Medicinal Chemistry and Early Development
|
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
|
2024-11-01, [In-Person] Clinical Pharmacology Studies on Hepatic and Renal Impairments for NDA Filing: Strategies, Design, Conduct, Analysis and Regulatory Aspects
|
2024-11-13, [Free Online Workshop] Career Transition for Research Scientists: Business Development & BioPartnering
|
2024-11-15, [In-Person] Current State of Bioanalysis for Biologics and Cell/Gene Therapy Products: Refining Established Approaches for New Complex Therapies
|
2024-12-13, Why All These New Modalities?
|
2025-01-22, [In-Person] Small-Molecule Formulation for Discovery & Early Development (jointly by PBSS / AAPS-BADG / Syner-G)
|
2025-02-06, [In-Person] Intellectual Property (IP) Strategies and Best Practices
|
|
Ads (in random order)
Submit a Text Ad ($250 for 2 months)
Simulations Plus
GastroPlus X: Science, models & refined algorithms—now with intuitive interface, faster processing & streamlined workflows for faster PBPK modeling.
|
Allucent
Bringing innovation to Biotech w/ClinPharm Modeling & Simulation services to inform dose, design, modeling + development strategies.
|
Alturas Analytics, Inc.
Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
|
PharmaResources
Top-tier small molecule CRO/CDMO offering comprehensive supports from Medicinal Chemistry, DMPK, and CMC to GMP manufacturing for commercialization.
|
Submit a Text Ad
|